| Date | Title | | | 12/07/11 | Rigel to Present at Oppenheimer Annual Healthcare Conference| SOUTH SAN FRANCISCO, Calif., Dec. 7, 2011 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief operating officer, is scheduled to present a company overview at the Oppenheimer 22nd Annual Healthcare Conference in New York City on Wednesday, December 14th at 1:00 p.m. ET.
(Logo: http://photos.prnewswire.com/prnh/20030226/RIGLLOGO)
To access the live audio webcast of the company presentation or the subse... |
|  | | 11/03/11 | Rigel to Participate at Two Upcoming Investor Conferences| SOUTH SAN FRANCISCO, Calif., Nov. 3, 2011 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Ryan Maynard, executive vice president and chief financial offer of Rigel, will participate at two investor conferences in November. Details of the events are as follows:
(Logo: http://photos.prnewswire.com/prnh/20030226/RIGLLOGO)
2011 Credit Suisse Annual Health Care Conference
Date: Thursday, Novem... |
| | | 11/01/11 | Rigel Announces Third Quarter 2011 Financial Results| SOUTH SAN FRANCISCO, Calif., Nov. 1, 2011 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter and nine months ended September 30, 2011.
For the third quarter of 2011, Rigel reported a net loss of $17.9 million, or $0.25 per basic and diluted share, compared to a net income of $50.4 million, or $0.97 and $0.96 per basic and diluted share, respectively, in the same period of 2010. Basic weighted average shares outstanding... |
| | | 10/06/11 | Rigel to Webcast Investor Day on October 13, 2011| SOUTH SAN FRANCISCO, Calif., Oct. 6, 2011 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will provide a live webcast of its upcoming Investor/Analyst Day on Thursday, October 13, 2011 at 10:00am EDT. Members of Rigel's senior management team will provide an overview of the company's product pipeline, as well as discuss the Phase 2 strategy for R343, their inhaled syk inhibitor for asthma.
To view the multimedia assets associated with this relea... |
| | | 08/25/11 | Rigel to Present at Two Upcoming Investor Conferences| SOUTH SAN FRANCISCO, Calif., Aug. 25, 2011 /PRNewswire via COMTEX/ --
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Ryan Maynard, executive vice president and chief financial officer of Rigel, will present at two separate investor conferences in September. Details of the events are as follows:
Stifel Nicolaus Healthcare Conference 2011
Date: Thursday, September 8th at 10:20 a.m. ET
Location: ... |
| | | 08/02/11 | Rigel Announces Second Quarter 2011 Financial Results| SOUTH SAN FRANCISCO, Calif., Aug. 2, 2011 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter and six months ended June 30, 2011.
For the second quarter of 2011, Rigel reported a net loss of $21.5 million, or $0.37 per basic and diluted share, compared to a net income of $27.0 million, or $0.52 and $0.51 per basic and diluted share, respectively, in the same period of 2010. Basic weighted average shares outstanding for... |
| | | 06/16/11 | Rigel to Present at Wells Fargo Securities Healthcare Conference| SOUTH SAN FRANCISCO, Calif., June 16, 2011 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul R. Rodriguez, the company's president and chief operating officer, is scheduled to present a company overview at the Wells Fargo Securities 2011 Healthcare Conference in Boston, MA on Thursday, June 23rd at 9:30 a.m. ET.
To access the live audio webcast of the company presentation or the subsequent archived recording, log on to www.rigel.com. Please conne... |
| | | 06/03/11 | Rigel to Present at Jefferies Global Healthcare Conference| SOUTH SAN FRANCISCO, June 3, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Jefferies 2011 Global Healthcare Conference in New York City on Wednesday, June 8th at 2:30 pm ET.
The presentation will be webcast live and can be accessed at www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webca... |
| | | 05/26/11 | Rigel Announces Pricing of Public Offering of Common Stock| SOUTH SAN FRANCISCO, Calif., May 26, 2011 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced the pricing of its previously announced underwritten public offering of 16,300,000 shares of its common stock, offered at a price of $8.00 per share to the public. The gross proceeds to Rigel from this offering are expected to be approximately $130,400,000, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by Rigel. ... |
| | | 05/25/11 | Rigel Announces Proposed Public Offering of Common Stock| SOUTH SAN FRANCISCO, Calif., May 25, 2011 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by Rigel. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Jefferies & Comp... |
| | | 05/06/11 | Rigel Assumes Development Responsibility for Inhaled Asthma Therapy| Plans Phase 2 Clinical Trial of R343
SOUTH SAN FRANCISCO, Calif., May 6, 2011 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 clinical trials. Pfizer Inc. is returning full rights to the R343 program as a result of its decision to exit the allergy and respiratory therapeutic area within R&D. Rigel is evaluating the de... |
| | | 05/05/11 | Rigel to Present at Bank of America Merrill Lynch Health Care Conference| SOUTH SAN FRANCISCO, Calif., May 5, 2011 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Ryan Maynard, the company's chief financial officer, is scheduled to present a company overview at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on Tuesday, May 10th at 10:00 a.m. PT.
(Logo: http://photos.prnewswire.com/prnh/20030226/RIGLLOGO)
The presentation will be webcast live and can be accessed at www.rigel.com. Please connect t... |
| | | 05/03/11 | Rigel Announces First Quarter Financial Results| SOUTH SAN FRANCISCO, Calif., May 3, 2011 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2011.
For the first quarter of 2011, Rigel reported a net loss of $20.8 million, or $0.40 per share, compared to a net loss of $22.3 million, or $0.43 per share, in the first quarter of 2010. Weighted average shares outstanding for the first quarter of 2011 and 2010 were 52.3 million and 52.0 million, respectivel... |
| | | 03/01/11 | Rigel Announces Fourth Quarter and Year End 2010 Financial Results| SOUTH SAN FRANCISCO, Calif., March 1, 2011 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and year ended December 31, 2010.
For the fourth quarter of 2010, Rigel reported a net loss of $17.2 million, or $0.33 per share, compared to a net loss of $25.1 million, or $0.48 per share, in the fourth quarter of 2009. Weighted average shares outstanding for the fourth quarter of 2010 and 2009 were 52.2 million and 51.8 mi... |
| | | 02/28/11 | Rigel to Present at Three Upcoming Investor Conferences| SAN FRANCISCO, Feb. 28, 2011 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at three investment conferences during the month of March. Details of each conference are as follows:
Citi Global Health Care Conference
Date: Wednesday, March 2nd at 1:30 p.m. ET
... |
| | | 02/09/11 | Rigel Announces Participation at Two Investor Conferences| SOUTH SAN FRANCISCO, Calif., Feb. 9, 2011 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to participate at two investor conferences in New York City next week. Details of the events are as follows:
Tuesday, February 15 at 9:00 a.m. ET
13th Annual BIO CEO & Investor Conference
Pa... |
| | | 01/06/11 | Rigel to Present at JP Morgan Healthcare Conference| SAN FRANCISCO, Jan. 6, 2011 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the JP Morgan Healthcare Conference in San Francisco, CA on Thursday, January 13th at 11:30 a.m. PST.
(Logo: http://photos.prnewswire.com/prnh/20030226/RIGLLOGO)
To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Pl... |
| |
|
rigel in the news
